Based on the analysis of its November 2013 meeting, there were no real references to conditions in the economic or pricing sections of the PBAC's Public Summary Documents. At the November 2024 meeting, there were 160.
The PBAC's 'conditionality' and 'provisional' revolution from 2013 to 2024
August 21, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News

